NEWROTEX LIMITEDActive

Company number 11798939Private limited companyIncorporated 2019

Key figures

£452,580+19.7%
Net assets 2025/26
+65.5%
Average annual growth 2019/20–2025/26
0200 k400 k600 k2019/202020/212021/222022/232023/242024/252025/26

Like most small UK companies, NEWROTEX LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2025/26
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0200 k400 k600 k2019/202020/212021/222022/232023/242024/252025/26
Filed accounts2019/20–2025/26
2021/222022/232023/242024/252025/26
Total assets451,761476,972251,473278,942424,159
Total liabilities11,6168,152——8,747
Net assets / total equity441,045469,720229,656378,079452,580
Average number of employees45577

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Principal activity

Accounts 2026

72110

As described in the company's latest filed accounts.

Summary: NEWROTEX LIMITED

Company

NEWROTEX LIMITED is a private limited company registered with Companies House under company number 11798939. It was incorporated on 31 Jan 2019. Its status is active. The registered office is in Oxford (OX3). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).

Accounts

The latest accounts in the database are for 2025/26 (period ending 31 Jul 2026); the company files micro-entity accounts. Net assets were £452,580, up 19.7% on the previous year. Total assets were £424,159 and total liabilities £8,747. The company had an average of 7 employees. Figures are available for 7 financial years (2019/20–2025/26).

Control and charges

The company has 5 current directors. 2 persons with significant control are registered.

Filing deadlines

The next accounts are due by 30 Apr 2028. The next confirmation statement is due by 5 May 2027.